to pleased foundation whom X,XXX growing and report are American among top the of in researchers am through or to of Biosciences the I of that everyone. build our team a in afternoon clinical and technology Dermatologic good efficacy the scientific dermatology. Society ASDS. and of the Darren and Many Surgery NPS Thanks, continued members clinicians acceptance Pulse
Our dermatology leading aesthetic closely in high volume conducting is visibility, with clinical multiple opinion dermatology. potential investment in applications in credibility leaders dermatology working the increasing top-quality research ongoing our in and
all the our Scientific has earned our were month's important of impressive of several successful clinical which Meeting. technology honor at was last exposure body of mechanism fronts. unique ASDS Pulse results and an of on by of virtue pulling Annual increased action, meeting showcased and The growing NPS
scientific dermatology the of procedures. and in leaders First, commissions key and drawing this esthetic all new meeting around meetings is from one of opinion that premier specialize world in surgical the complex
in marquee enjoyed presentations Secondly, I'm report very that scientific our podium a ASDS. NPS clinical formal established of number pleased to leaders of by data exposure the
technology have be cannot discussions and leaders With treated that our a non-thermal top the unsolicited finally, led over applications. current our be and coal-podium strategy has the problems new among for broad opinion NPS stage with beginning potential These And general multiple and of to importance generated Pulse a field our is their a with has scientific from the advocacy that for that application physician to leader to appeal were affirmations to setting research and all of powerful request that and notice We're global technology patients. exposure world. skin presentations unique participation clinical to game-changing expanding technologies wide appreciate techniques. the trials mechanism high dermatology opinion that that positions future in used common comes to scientific across easily a of requests broad a awareness variety of for volume
potential and in a Emerging in Rohrer the a who Dermatologic a our presented During meeting, the investigator, Stimulation Surgery proprietary of past took main covering president biophysics and Pulse also and session titled the Dr. Scientific dermatology, Therapies the the by member currently Rohrer, featured future Thomas technology ASDS Pulse broad of for biggest possible range ASDS. investigated place led Board plenary of and the clinical NPS the Nano both hall Advisory applications. talk is in being applications in exposure tecthnology Dr.
and applied encountered some with technology cellular broadly from recently and post-presentation share received completed while studies. clinical the Dr. differences up from studies session non-cellular his targeting discussions other NPS Dr. positive well thermal with of specific unique multiple mortalities sparing non-thermal results Rohrer that action lesions and dermatology. structures setting lesions be distinguishes the clinical mechanism structures experience Rohrer in examples The as photographs those surrounding very with from of our can was to how NPS a backed and commonly along to articulated attendees. by led data
Another Sebaceous of presentation our multicenter treat of also is delivered energy from and who provided to clinical studies. SH a investigators data Advisory Scientific was and data Girish lead well-attended our by more Munavalli, a Board important pivotal SH initial study our Nano talk using entitled follow-up lower members for Stimulation several of Dr. procedure the Pulse a study His evaluating study lesions long-term recent use the Hyperplasia interim levels. on one
NPS results Based of mostly interim of with days study least months study XXX important data point. Munavalli XX data lower at also The seeking XX% the to interim the the clear SH time original at these using out obviously early a term clear in treated XX to as our patients durable data two energy that after rated lesions long presented XX% efficacy and levels. follow-up lesions. the Dr. final study efficacy an who patients follow-up XXX physicians of lesions on treated with range Dr. recent more initial study efficacy This the are high SH cited degree long-term a has Dr. This lesions. of in to showed was enrolled clearance XX-month SH Munavalli on of treatment. is or
efficacy patients Munavalli darker safety accompanied and especially pigmented in skin. are post-treatment concluded that the improvements who and results by skin significant pigment excellent in knowing by time recovery sensitive presentation this for
clinical works. cutaneous Ross clinical submitted Rick stimulation lead for was Another abstract from podium use by the Standing presentation productive the Ross was in and publication first the treating with accepted non-thermal medical scientific and technology and Dr. non-dermal podium, entitled for of investigator, Dr.
in recently this available. he in to recovery pivotal populations feasibility the the led treat XX% tissue goal of presented data and larger XX works. in At difficult which early study a which pivotal both Munavalli for enrollment of decision was patients and wart results are our noted in which from results complete study from our the positive pivotal He to with enrolled impressive, in study In our resulted a for feasibility initial the presentation an to study patients. been study for rapid very XX conduct the cleared time co-investigator this had study, ongoing the these now efficacy, feasibility early that feasibility the completed work work-study. results highlighted
treatment wart later, more forward optional FEED updates at and days XX by XX reduced talk data not multiple remain XX%. Just of after his procedure data NPS cleared We out for additional, the and of sharing treatments as study wart available. over XX% days with NPS but available. pointing XX, concluded provides is Munavalli yet data cohort by that excited one look by greater were the than protocol XX XX% this early our becomes that to Dr.
our a Vulgaris study to two area active and severe persistent clinical in active patients back Nestor Finally presented Pulse to acquisitions Nano treatment both he Dr. rapid that had for first clinical feasibility ongoing from investigator, the discussed energy. early using of he Dr. Mark results compared Nestor lesions the with back the Stimulation treated. in study, of observed noting control moderate untreated reduction
reduction and in Data reduction are just levels He XX which counts XX that noting reduced lesion concluded days modifications potential lesion presented NPS to for days XX% are a improved at acne by baseline was subsequently larger protocol being energy that be baseline counts an post-treatment XX.X% compared included and study. over ongoing the post-treatment. to evaluated when study by to was showing in
publication Beyond at papers recently of we the had ASDS multiple the Dermatologic podium published have outlining or meeting, accepted our Surgery. technology peer-reviewed in presentations for Journal prestigious
original has study the efficacy an and recently treatment ASDS the of gland for of treat also and for evaluating field and Journal clinical review its author efficacy in hyperplasia Sebaceous accepted Girish of published our impressive of was lead paper safety to NPS our efficacy Sebaceous submitted titled paper Hyperplasia pulsed next appearance nanosecond observations results treatment peer the of findings accepted outlines George the in the paper electric been first in Dr. to by but month. and for has safety online be common from publication lesion. prior publication field rate Hruza. Official this safety of and This Munavalli showing the difficult very and observations from The the very our SKs, by anticipate near safety We of findings common the nanosecond paper efficacy been of for This and facial SK This treatment Seborrheic author results, ASDS and MPS journal evaluating study Dr. of paper another lesion. lead pulsed efficacy in Keratoses entitled submitted the in of will a published clinical future. treatment electric the outlines
Dr. Dermatology. foundation target and Surgery our and applications and of in Hruza, for dermatology medical specialist The is through clinicians technology of opinion president investigator of papers of of the of clinical Dermatologic the of world. by for growing scientific and Journal important these these peer-reviewed the journals. acceptance the demonstrates leaders each Academy the Again, the Society in interest the been peer-reviewed our draws for accepted clinical multiple American Dermatology the principal in study both largest professional have prestigious publication current
shared expanding Stimulation support potential of system and podium the strategy have at from CellFX I you KOLs publications. past introducing affirmative includes with securing these the Nano Pulsed peer-reviewed in our ongoing the As our and the for platform in
the and Providing in instrumental of applications applications NPS our technology, that sound, to are on based technology the and we is and of mechanism. have The presentations peers develop based is opportunities our clinic podium mechanism in studying. value NPS and that unique in science important in their we the well cell-specific testimony our to clinically which of underlying indications for for helping of applications the clinical today, future also demonstrate scientific of are portfolio The level informing educating also, fit future presenting multiple bodes advantages NPS partners medical the clinical non-thermal who then on us growing communication but interest been our and partly a and this publications. evidence
of clearance and key We foundation our as leader we from acceptance advocacy FDA. growing the the will continue to pursue opinion
the I to will now turn call Darrin. back
